New therapeutic perspectives on protein-bound uremic toxins in chronic kidney disease

Bibliography

• Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19:863-70
   PubMed Web of Science ®Google Scholar
• Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43
   PubMed Web of Science ®Google Scholar
• Niwa T. Targeting protein-bound uremic toxins in chronic kidney disease. Expert Opin Ther Targets 2013;17(11):1287-301
   Web of Science ®Google Scholar
• Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B 2010;878:1662-8
   PubMedGoogle Scholar
• Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;114;S12-19
   Web of Science ®Google Scholar
• Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens 2008;17:560-5
   PubMed Web of Science ®Google Scholar
• Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007;357:1316-25
   PubMed Web of Science ®Google Scholar
• Meijers BK, De Loor H, Bammens B, et al. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-8
   PubMed Web of Science ®Google Scholar
• Vanholder R, Meert N, Schepers E, et al. Review on uraemic solutes II-variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 2007;22:3115-21
   Google Scholar
• Martinez AW, Recht NS, Hostetter TH, et al. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005;16:3430-6
   PubMed Web of Science ®Google Scholar
• Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009;54:891-901
   PubMed Web of Science ®Google Scholar
• Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-56
   PubMed Web of Science ®Google Scholar
• De Smet R, David F, Sandra P, et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998;278:1-21
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-8
   PubMed Web of Science ®Google Scholar
• Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012;43:451-6
   PubMed Web of Science ®Google Scholar
• Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011;6:30-9
   PubMed Web of Science ®Google Scholar
• Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-77
   PubMed Web of Science ®Google Scholar
• Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-67
   PubMed Web of Science ®Google Scholar
• Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007;11:189-95
   Google Scholar
• Ueda H, Shibahara N, Takagi S, et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008;30:856-60
   PubMed Web of Science ®Google Scholar
• Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011;26:938-47
   PubMed Web of Science ®Google Scholar
• Konishi K, Nakano S, Tsuda S, et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;81:310-5
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kawagoe Y, Matsuda T, et al. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004;27:121-6
   PubMed Web of Science ®Google Scholar
• Shibahara H, Shibahara N. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010;23:535-40
   Google Scholar
• Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011;26:1094-8
   PubMed Web of Science ®Google Scholar
• Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012;7:982-8
   PubMed Web of Science ®Google Scholar
• Lesaffer G, De Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-7
   PubMed Web of Science ®Google Scholar
• Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278-85
   Google Scholar
• De Smet R, Dhondt A, Eloot S, et al. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007;22:2006-12
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;70:794-9
   Google Scholar
• Meert N, Beerenhout C, Schepers E, et al. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009;22:352-7
   Google Scholar
• Meert N, Waterloos MA, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs 2010;34:580-5
   Google Scholar
• Meert N, Eloot S, Schepers E, et al. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 2011;26:2624-30
   PubMed Web of Science ®Google Scholar
• Meijers BK, Weber V, Bammens B, et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2008;32:214-9
   PubMed Web of Science ®Google Scholar